AVITA Medical (RCEL) to Release Quarterly Earnings on Thursday

AVITA Medical (NASDAQ:RCEL - Get Free Report) is projected to release its earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.

AVITA Medical (NASDAQ:RCEL - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.14). The business had revenue of $18.41 million during the quarter, compared to the consensus estimate of $18.40 million. AVITA Medical had a negative net margin of 96.26% and a negative return on equity of 337.91%. On average, analysts expect AVITA Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AVITA Medical Stock Down 2.0 %

Shares of NASDAQ:RCEL traded down $0.20 during midday trading on Friday, hitting $9.75. 259,662 shares of the company's stock were exchanged, compared to its average volume of 178,464. The company has a debt-to-equity ratio of 9.39, a current ratio of 2.83 and a quick ratio of 2.47. AVITA Medical has a 12 month low of $7.51 and a 12 month high of $18.93. The company has a market cap of $255.65 million, a PE ratio of -4.08 and a beta of 1.55. The stock has a 50 day moving average price of $10.40 and a 200-day moving average price of $10.63.

Analyst Ratings Changes

A number of analysts have commented on RCEL shares. D. Boral Capital decreased their price objective on AVITA Medical from $25.00 to $22.00 and set a "buy" rating for the company in a report on Thursday. Lake Street Capital decreased their price target on AVITA Medical from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, January 8th. Cantor Fitzgerald restated an "overweight" rating and set a $21.00 price objective on shares of AVITA Medical in a research note on Tuesday, December 24th. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $12.00 price objective (up from $9.00) on shares of AVITA Medical in a report on Friday, November 8th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, AVITA Medical has an average rating of "Moderate Buy" and a consensus target price of $17.25.

Insider Activity at AVITA Medical

In related news, Director Robert Mcnamara bought 10,000 shares of the company's stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $10.09 per share, for a total transaction of $100,900.00. Following the completion of the purchase, the director now directly owns 45,749 shares in the company, valued at $461,607.41. The trade was a 27.97 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Over the last three months, insiders acquired 12,461 shares of company stock valued at $129,689. 1.82% of the stock is owned by insiders.

About AVITA Medical

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.